All News | RheumNow

All News

RheumNow Podcast square

Intrathecal Methotrexate for Cerebritis (3.31.2023)

Save

d Jack Cush, MD

Mar 31, 2023

Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow.com.

Read Article

Alcohol Differences in Urate Level Elevation

Save

d Jack Cush, MD

Mar 30, 2023

Does serum urate elevation differ with different types of alcohol consumption? A Japanese study shows beer and wine was associated with high and moderate increases in uric acid but less so with sake.

Read Article

LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/RYmb3QFB1T https://t.co/sn5hwVxwPk

Links:

https://bit.ly/3ZvUw1U

Dr. John Cush RheumNow ( View Tweet)

Apr 02, 2023

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/lvPO26S0k6 https://t.co/cQtiEctrTR

Links:

https://bit.ly/3K4tSHL

Dr. John Cush RheumNow ( View Tweet)

Apr 02, 2023

30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/dsbjPhuYzf https://t.co/1Zmyqjuaxj

Links:

https://bit.ly/3ZspPdH

Dr. John Cush RheumNow ( View Tweet)

Apr 02, 2023

Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/C0WA2Znixl https://t.co/vXzL8XR7kd

Links:

https://bit.ly/3U1UcXt

Dr. John Cush RheumNow ( View Tweet)

Apr 01, 2023

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/2DCn53Rk4z https://t.co/sZYhgfCU0E

Links:

https://bit.ly/42TKNVU

Dr. John Cush RheumNow ( View Tweet)

Apr 01, 2023

Intrathecal Methotrexate for Cerebritis Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow. https://t.co/wTOehtaU27 https://t.co/8Xp0C6tqBe

Links:

https://bit.ly/3nDEMwr

Dr. John Cush RheumNow ( View Tweet)

Apr 01, 2023

Join RheumNow during the month of April as we discuss Women in Rheumatology, the XX Factor. Sign up to attend our series! https://t.co/e3AJKwnoWs https://t.co/cpUmsOVuAT

Links:

https://bit.ly/3K4apGU

Dr. John Cush RheumNow ( View Tweet)

Mar 31, 2023

Network metaanalysis of 7 dietary RCTs in high risk CV pts (40 RCTs, 35 548 pts), showed only Mediterranean (OR 0.72) & low fat (OR 0.84) diet reduce all cause mortality; Med-diet also reduced CV mortality (0.55), stroke (0.65) & non-fatal MI (0.48) https://t.co/ibUknLlwOx https://t.co/zRtvXObvg3

Links:

https://bit.ly/40NtS5t

Dr. John Cush RheumNow ( View Tweet)

Mar 31, 2023

RCT shows vitamin D does not improve psoriasis. 122 mild PSO pts (PASI=3.1) w/ mean low vit D levels 14.9 ng/mL; randomized to vit D (20KIU/wk) or placebo. At 4 mos, vit D levels rose to 30 w/ Rx, but no signif improvement in PASI change, MD global or DLQI https… https://t.co/OI5v1y5t0u

Dr. John Cush RheumNow ( View Tweet)

Mar 31, 2023

There are 27 US States where Nurse Practitioners have "Full Practice Authority" - including WA, OR, NV, ID, UT, MT, AZ, CO, WY, NM, ND, SD, NE, KS, Minn, NY, ME, VT, NH, MA, CT, RI, MD, DE, DC https://t.co/hA9Sd63bDW https://t.co/9MM6CTH4gX

Links:

https://bit.ly/42VA11y

Dr. John Cush RheumNow ( View Tweet)

Mar 31, 2023

203 Rheumatology Clinical trials .gov; after 30 mos 17% are unpublished. Published were more likely to be Phase 3 (57% v 29%) or have +primary outcome (65% vs 26%). Unpub authors cite ongoing preparation, sponsor issues, negative results https://t.co/zSxt0W9ZhB https://t.co/k9rCUSel3e

Links:

https://bit.ly/3lYb8S7

Dr. John Cush RheumNow ( View Tweet)

Mar 31, 2023

Bimekizumab in Hidradenitis Supprativa (HS) - results of 2 phase III BE HEARD I & II trials show Week 16 50% HS Responses to be 48% and 52% (vs PBO 29% and 32%). >75% maintained response out to wk 48; at wk 48, a 75% HS response seen in 55%. https://t.co/ZxJylP7IUk https://t.co/Kmx1dkHycM

Links:

https://bit.ly/3zhrpVl

Dr. John Cush RheumNow ( View Tweet)

Mar 31, 2023

The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu . https://t.co/nzuHh6v0ua

Links:

https://bit.ly/40thmIM

Dr. John Cush RheumNow ( View Tweet)

Mar 31, 2023

Frunevetmab (Solensia), is a cat-specific mAb against nerve growth factor was FDA approved, for use in CATS, to treat the pain of osteoarthritis. CATS! https://t.co/mqmQ7jzbpj https://t.co/9FrIOAYJwA

Links:

https://bit.ly/3nARvQw

Dr. John Cush RheumNow ( View Tweet)

Mar 31, 2023

Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/1ZiRX3jUGV https://t.co/k0a54QJ9Hi

Links:

https://bit.ly/3G9lVzF

Dr. John Cush RheumNow ( View Tweet)

Mar 30, 2023

2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/kX3dg9DGuw https://t.co/b27CX6Bn0h

Links:

https://bit.ly/3G44JeY

Dr. John Cush RheumNow ( View Tweet)

Mar 30, 2023

LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/VWs0YuF4LD https://t.co/7ydA3bb82j

Links:

https://bit.ly/3FZ7z4H

Dr. John Cush RheumNow ( View Tweet)

Mar 30, 2023

Docs' Liking for Knee Injection Tied to Industry Payments Physicians accepting payments from drug and device companies administered significantly more hyaluronic acid (HA) injections to Medicare beneficiaries for knee osteoarthritis, researchers found. https://t.co/REtzVjldl2 https://t.co/gfj5cwmVqs

Links:

https://bit.ly/3G4SU8f

Dr. John Cush RheumNow ( View Tweet)

Mar 30, 2023

×